Happy New Year – 2016

It’s been an interesting year. When I started this site I really didn’t know what was going to happen… in most respects, it has exceeded my expectations. A Few Opening Remarks On a positive note, I genuinely felt support for the mission of trying to create a fresh dialogue around the quality and transparency of ASX-listed companies operating in this…

Twenty Questions for Phosphagenics

Apologies in advance for what is a fairly long post… In the usual stream of announcements and news feeds yesterday, I read the ASX release from Phosphagenics (ASX : POH) regarding their Oxycodone PHN study. Now I don’t comment much on this company, despite the fact that they are fairly visible in the public domain. About…

ACL : Live and Let Die?

I love a good Bond film and my favorite is, without hesitation, “Live and Let Die”. Charismatic villains, gorgeous but complex “starlets”, and Roger Moore at his gorgonzola-best. McCartney’s awesome sound track is surprisingly glam rock for the era, reminding us that after all the optimism and hope of youth – “live and let live” – is…

Novogen’s “Comprehensive Science Review”

What a complete and utter farce. At the end of July, acting CEO Iain Ross informed that markets that he would be conducing a systematic review of Novogen’s (ASX : NRT) prospects, with the goal of a shareholder update by the 1st of September. Today, we received the promised progress update in the form of…

Entrepreneurs, take heart…

Any of you reading this who has ever raised money or been on the road, been involved in business development or sales, will know the feeling I am about to describe. After a very excellent day of meetings in Sydney, mostly around raising some philanthropic funds for a project I am working on, I got to…

The 2000 Mile Rule

When I was a kid, my Dad and I drove across the Nullarbor Plain, from Adelaide to Perth. I will never forget the experience and it rests in my mind as one of the most visually spectacular stretches of road I have ever driven along. It also very much reinforced my perception of how remote and far-flung…

The Incest of ASX Biopharma

It’s pretty hard to beat the Brits when it comes to situational comedy. As a dual-Australian/Canadian national educated in the UK, I suppose I have an intrinsic affinity for that dry, offhand style of humour. A few years ago, I stumbled across a brilliant comedy skit that visually captures precisely the fundamental reason why ASX biopharma is…